Ozempic
Payments companies reported to CMS as associated with Ozempic. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Ozempic, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Ozempic
These are the largest totals companies reported as associated with Ozempic. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Joshua Stolker | Washington, MO | Interventional Cardiology | $126,976.68 |
| Benjamin Kalsmith | Pgh, PA | Cardiovascular Disease | $126,034.09 |
| Michael Shannon | Lacey, WA | Endocrinology, Diabetes & Metabolism | $113,018.57 |
| Aaron King | San Antonio, TX | Family Medicine | $109,625.85 |
| Steve Fordan | Dallas, TX | Endocrinology, Diabetes & Metabolism | $105,568.24 |
| Robert Busch | Albany, NY | Endocrinology, Diabetes & Metabolism | $102,818.22 |
| Christopher Lucci | Rockport, TX | Public Health & General Preventive Medicine | $102,476.55 |
| Patrick Cambier | Trinity, FL | Interventional Cardiology | $102,399.91 |
| Rakesh Shah | Langhorne, PA | Cardiovascular Disease | $99,687.63 |
| Craig Wierum | Nashville, TN | Endocrinology, Diabetes & Metabolism | $99,659.84 |
Prescribed Ozempic?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.